Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure

Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure

Background Angiotensin receptor neprilysin inhibitors (ARNI) reduce mortality and hospitalization for patients with heart failure. However, relatively high copayments for ARNI may contribute to suboptimal adherence, thus potentially limiting their benefits. Methods and Results We conducted a retrosp...

Full description

Bibliographic Details
Main Authors:	Amrita Mukhopadhyay, Samrachana Adhikari, Xiyue Li, John A. Dodson, Ian M. Kronish, Binita Shah, Maggie Ramatowski, Rumi Chunara, Sam Kozloff, Saul Blecker
Format:	Article
Language:	English
Published:	Wiley 2022-12-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	angiotensin receptor‐neprilysin inhibitor copayment heart failure medication adherence out‐of‐pocket cost sacubitril‐valsartan
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.122.027662

Similar Items

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021-09-01)

Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction – “ARNI-PRESERVED” study
by: Pankaj Jariwala, et al.
Published: (2021-01-01)

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
by: Brittany Chapman, et al.
Published: (2022-06-01)

Initiation, treatment response evaluation, and safety monitoring of angiotensin receptor/neprilysin inhibitors (Sacubitril/Valsartan) in the management of heart failure in India: An expert group recommendations
by: Uday M Jadhav, et al.
Published: (2023-01-01)

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
by: Wanjing Li, et al.
Published: (2022-04-01)

The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Sharath Kommu, et al.
Published: (2024-03-01)

Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity
by: Aleksandra M. Sobiborowicz-Sadowska, et al.
Published: (2023-01-01)

Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial
by: Julie Hempel Larsen, et al.
Published: (2023-02-01)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
by: Katie L. Peppin, et al.
Published: (2020-01-01)

Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial
by: Adam D. DeVore, et al.
Published: (2018-06-01)

Patient perceptions of copay card utilization and policies
by: Dimika Cavalier, et al.
Published: (2023-12-01)

Sacubitril/valsartan attenuates atrial conduction disturbance and electrophysiological heterogeneity with ameliorating fibrosis in mice
by: Satoshi Iwamiya, et al.
Published: (2024-01-01)

INNOVATIVE STRATEGY IN THERAPY OF CARDIAC INSUFFICIENCY
by: N. A. Jaiani
Published: (2017-11-01)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
by: Valeria Visco, et al.
Published: (2022-10-01)

Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor
by: Teng Y, et al.
Published: (2023-08-01)

Clinical Outcomes in Patients with Ischemic versus Non-Ischemic Cardiomyopathy after Angiotensin-Neprilysin Inhibition Therapy
by: Mohammad Abumayyaleh, et al.
Published: (2021-10-01)

Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out‐Of‐Pocket Expenses? Insights From ARTEMIS
by: Jennifer A. Rymer, et al.
Published: (2022-10-01)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
by: Ying Ding, et al.
Published: (2023-12-01)

Combined drug sacubitril/valsartan -a new era of treatment of chronic heart failure
by: V. S. Nikiforov
Published: (2020-10-01)

Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials
by: Yake Lou, et al.
Published: (2022-08-01)

Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure
by: Yuxi Sun, et al.
Published: (2022-02-01)

Moving Beyond Self‐Reported Race in Our Understanding of Cardiovascular Medicine
by: Nancy Luo
Published: (2022-06-01)

Impact of the change of copay policy in Medicare Part D on zoster vaccine uptake among Medicare beneficiaries in a managed care organization
by: Rulin C. Hechter, et al.
Published: (2017-07-01)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01)

Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy
by: Wei-Chieh Lee, et al.
Published: (2023-04-01)

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
by: Hisham A. Badreldin, et al.
Published: (2022-02-01)

Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
by: Marina Nikolic, et al.
Published: (2022-11-01)

Reduced economic disparity in biologics use for psoriasis after introducing the reducing copayment program
by: Hyemin Jung, et al.
Published: (2024-02-01)

COPAYMENTS OF THE CITIZENS IN HEALTHCARE SYSTEM: INTERNATIONAL PRACTICE
by: A. P. Tatarinov, et al.
Published: (2016-12-01)

Frecuencia y distribución geográfica del uso de sacubitril/valsartán en Colombia entre los años 2019 y 2020
by: Nancy Herrera-Leaño, et al.
Published: (2024-01-01)

Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?
by: Nechita Alexandru Cristian
Published: (2022-12-01)

Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
by: Tomoko Kato, et al.
Published: (2023-09-01)

Benefits of Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure with Reduced Ejection Fraction: A Longitudinal Study
by: Dharmendra Jain, et al.
Published: (2022-04-01)

Efficacy and Safety of Angiotensin Receptor Neprilysin Inhibitor versus Angiotensin Converting Enzyme Inhibitor in Heart Failure with Reduced Ejection Fraction- A Prospective Observational Study from a Major Tertiary Care Hospital, Assam, India
by: Bornali Dutta, et al.
Published: (2022-10-01)

Is Sacubitril/Valsartan a Safe and Effective Option in Real World Patients with Mild to Severe Chronic Kidney Disease?
by: Marta Afonso Nogueira, et al.
Published: (2022-07-01)

Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure – A prospective observational study
by: Tahir Saleem Bhat, et al.
Published: (2022-05-01)

REVIEW OF THE INTERNATIONAL PRACTICE OF COST-SHARING MECHANISM IN NATIONAL HEALTH CARE SYSTEMS
by: Natalia Nikolayevna Sisigina, et al.
Published: (2015-09-01)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
by: Maura Brioschi, et al.
Published: (2023-03-01)

Sacubitril/Valsartan Ameliorates Crizotinib-Induced Cardiotoxicity in Mice
by: Lijun Cheng, et al.
Published: (2023-07-01)

The effects of sacubitril/valsartan and ramipril on the male fertility in hypertensive rats
by: Duygun Altıntaş Aykan, et al.
Published: (2020-10-01)